cas 3034-38-6|| where to buy 4-nitro-1H-imidazole

Product Name:4-nitro-1H-imidazole

IUPAC Name:4-nitro-1H-imidazole

Packing Unit	Available Stock	Price($)
CM112444-500g	in stock	ȀƄ
CM112444-1000g	in stock	Ľǯǯ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3034-38-6 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:3034-38-6; Molecular Formula:C3H3N3O2; Melting Point:-; Smiles Code:O=[N+](C1=CNC=N1)[O-]; Density:

: Catalog Number:CM112444; Molecular Weight:113.08; Boiling Point:; MDL No:MFCD00005196; Storage:Store at room temperature

: Imidazoles; Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.; Imidazole Manufacturer; As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

: Ogsiveo; The FDA has approved Ogsiveo (Nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. The FDA approval of Ogsiveo is based on the results from the Phase 3 DeFi trial. The results showed that Ogsiveo met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). Ogsiveo is an oral, selective, small molecule gamma secretase inhibitorγ. Gamma secretase cleaves multiple transmembrane proteins, including Notch, that are believed to play a role in activating pathways that contribute to growth of desmoid and ovarian granulosa cell tumors.